Sorafenib to prevent relapse after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether the drug sorafenib can prevent blood cancer from returning after a stem cell transplant. It is for people who had a special combination of chemotherapy (bendamustine and cyclophosphamide) during their transplant and are at high risk for relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stem cell transplant that included the drugs bendamustine and cyclophosphamide.
- You have a high-risk blood cancer, such as acute myeloid leukemia that wasn't in remission before transplant, or certain genetic subtypes.
- A bone marrow test after transplant shows your cancer is in remission, even if a tiny amount is still detectable.
- You are within the first 100 days after your transplant.
- Your cancer has not come back after the transplant and been treated.
- Your heart, lungs, liver, and kidneys are working well enough, and you do not have serious infections or other health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two chemotherapy drugs (bendamustine and cyclophosphamide) given before a stem cell transplant to help prevent graft-versus-host disease. It is for people with high-risk blood cancers who don't have a fully matched donor and will receive a partially matched transplant.
This trial tests a new approach to reduce the chance of leukemia or other blood cancers coming back after a stem cell transplant. It uses careful monitoring before the transplant to try to prevent relapse.
This study tests whether a medication called IFN-α can help prevent the blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancers who are at high risk of relapse.
This trial tests a combination of three medicines (sirolimus, ruxolitinib, and mycophenolate mofetil) to prevent graft-versus-host disease (a common complication after a stem cell transplant) in people who cannot take standard anti-rejection drugs. The goal is to find a safer alternative that still protects you from this complication.
This trial tests combining two drugs, sorafenib and venetoclax, as a preemptive therapy to eliminate leftover leukemia cells (MRD) in people with AML who are in remission. The goal is to prevent the disease from coming back.
This trial tests whether giving medication after a donor stem cell transplant can prevent the return of very high-risk myelodysplastic syndrome (MDS). It is for people who have a suitable donor and are healthy enough for the procedure.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.